跳至主要内容
临床试验/IRCT20210825052293N1
IRCT20210825052293N1招募中3 期

Evaluation of the effect of selenium supplemention on cancer-related fatigue in outpatient cancer patients and comparison of it with placebo effect in control group

Esfahan University of Medical Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
30 years 至 60 years(—)
性别
All

入选标准

  • 30 to 60 years of age
  • To be able to read and write
  • Definitive diagnosis of cancer which requires chemotherapy and has been confirmed with pathology findings and authenticated by an oncology subspecialist
  • Not having another treatment regimen that has healing effect on fatigue
  • To have cancer-related fatigue and score of 40 and above in fatigue questionnaire
  • To tolerate oral medication
  • To cooperate and agree with the study

排除标准

  • Patients with known depression undergoing treatment
  • Having anemia
  • Having a disease that prevents patient from continuing participation in study
  • When more than 20% of the questionnaire has not been completed
  • Pregnancy and lactation
  • Renal failure
  • Taking medications such as baloxavir, marboxil, deferiprone, cabotegravir, bisphosphonate derivatives, bictegravir, dolutegravir, eltrombopag, trientine, raltegravir, penicillamine, elvitegravir
  • Known allergy to selenium
  • Hypothyroidism
  • Skin cancer and individulas at high risk for developing squamous cell carcinoma

研究者

相似试验